Tasosartan

Jump to: navigation, search
Tasosartan
Tasosartan.png
Clinical data
ATC code
Identifiers
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H21N7O
Molar mass411.459 g/mol

WikiDoc Resources for Tasosartan

Articles

Most recent articles on Tasosartan

Most cited articles on Tasosartan

Review articles on Tasosartan

Articles on Tasosartan in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tasosartan

Images of Tasosartan

Photos of Tasosartan

Podcasts & MP3s on Tasosartan

Videos on Tasosartan

Evidence Based Medicine

Cochrane Collaboration on Tasosartan

Bandolier on Tasosartan

TRIP on Tasosartan

Clinical Trials

Ongoing Trials on Tasosartan at Clinical Trials.gov

Trial results on Tasosartan

Clinical Trials on Tasosartan at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tasosartan

NICE Guidance on Tasosartan

NHS PRODIGY Guidance

FDA on Tasosartan

CDC on Tasosartan

Books

Books on Tasosartan

News

Tasosartan in the news

Be alerted to news on Tasosartan

News trends on Tasosartan

Commentary

Blogs on Tasosartan

Definitions

Definitions of Tasosartan

Patient Resources / Community

Patient resources on Tasosartan

Discussion groups on Tasosartan

Patient Handouts on Tasosartan

Directions to Hospitals Treating Tasosartan

Risk calculators and risk factors for Tasosartan

Healthcare Provider Resources

Symptoms of Tasosartan

Causes & Risk Factors for Tasosartan

Diagnostic studies for Tasosartan

Treatment of Tasosartan

Continuing Medical Education (CME)

CME Programs on Tasosartan

International

Tasosartan en Espanol

Tasosartan en Francais

Business

Tasosartan in the Marketplace

Patents on Tasosartan

Experimental / Informatics

List of terms related to Tasosartan

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tasosartan is an angiotensin II receptor antagonist.

It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]

References

  1. Atkinson AJ; et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 0-12-369417-5.
  2. Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm. 57 (13): 1231–41. PMID 10902066.

Linked-in.jpg